Porton Biopharma opens new leukaemia drug production facility
May 1, 2018Manufacturing and Production Porton Biopharma, leukaemia, pharma
Porton Biopharma Limited (PBL) has officially opened the doors of its new fermentation facility. John Glen, MP for Salisbury and …
Ovarian cancer rates set to rise by 55%
May 1, 2018Manufacturing and Production, Medical Communications biotech, drugs, ovarian cancer, pharma, pharmaceutical
Ahead of World Ovarian Cancer Day on 8 May, new figures have been released suggesting that rates of this type …
United Therapeutics to acquire SteadyMed for $216 million
May 1, 2018Manufacturing and Production, Sales and Marketing SteadyMed, UnitedTherapeutics, acquisition, pharma
United Therapeutics is set to acquire speciality pharma firm SteadyMed after it emerged that the pair had signed a definitive …
Novartis reveals more data for Eylea rival
May 1, 2018Manufacturing and Production, Research and Development biotech, drugs, pharma, pharmaceutical
Building on the back of strong data released at the end of last year, Novartis has released further positive Phase …
Lilly hires new leader of immuno-oncology
May 1, 2018Manufacturing and Production, Medical Communications Eli Lilly, biotech, drugs, immunoconlogy, immunotherapy, pharma, pharmaceutical
Immuno-oncology has become a huge area of the oncology market, led by the wave of PD-1/L1 drugs that are reaping …
Connecting patients to doctors
April 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, pharma, pharmaceutical
Dan Vahdat, CEO and Co-founder of Medopad, discusses the rapid expansion of the app he helped develop, as its mobile …
EMA’s CHMP backs Roche’s Perjeta combo in HER2-positive breast cancer
April 30, 2018Sales and Marketing Cancer, Herceptin, Perjeta, Roche, breast cancer, pharma
Roche’s Perjeta has edged one step closer to approval as a combo therapy after the EMA’s Committee for Medicinal Products …
Alzheon shies away from $81m IPO
April 30, 2018Sales and Marketing Alzheon, biotech, drugs, pharma, pharmaceutical
Alzheon, a tiny biotech based in the Boston area, had initially launched its roadshow for an IPO potentially worth up …
Allergan unveils second bout of Phase 3 success in migraine
April 30, 2018Research and Development, Sales and Marketing Allergan, migraine, pharma, ubrogepant
Allergan has revealed new data from the second of two Phase 3 studies into the efficacy of its calcitonin gene-related …
US applies pressure on Canada to stem cross-border generics flow
April 30, 2018Sales and Marketing Canada, IP, US, biotech, drugs, pharma, pharmaceutical
The US has upped the ante against Canada to secure stronger border checks for pharmaceutical goods by adding the country …
Navigating CMC Requirements during drug development and post-approval
April 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing dia
This training will offer you the overview of the existing regulatory aspects of the CMC, and will also give you …
Juno CEO and Co-founder steps down in wake of Celgene acquisition
April 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Celgene, Juno, appointment, pharma
Hans Bishop, CEO and Co-founder of Juno Therapeutics who helped set up the company in 2013 and has since grown …
Sanofi makes ex-Roche scientist new R&D chief
April 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Roche, Sanofi, appointment, pharma
With the retirement of Elias Zerhouni as Head of Global R&D, Sanofi had to find a suitable replacement and believes …
Top Ten most popular articles on Pharmafile.com this week
April 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Eli Lilly, FDA, Fresenius, Shire, Takeda, arthritis, pharma
The year seems like it’s running away as we come to the end of April. It’s been a more tense …
Eli Lilly partners with Chinese institution to advance the nation’s diabetes and CVD care
April 27, 2018Medical Communications, Research and Development China, Eli Lilly, cardiovascular disorders, cvd, diabetes, pharma, type 2 diabetes
EIi Lilly has announced plans to partner up with China’s National Center for Cardiovascular Diseases (NCCD), the nation’s institution responsible …
Two FDA drug review Directors to leave the agency, with no permanent replacements in place
April 27, 2018Medical Communications, Sales and Marketing FDA, pharma
The FDA has revealed that two of its prominent Directors are set to retire from the agency, leaving three of …
Investigational Alexion drug proves non-inferior to Soliris in rare blood disease
April 27, 2018Medical Communications, Research and Development Alexion, paroxysmal nocturnal haemoglobinuria, pharma, soliris
Alexion has lifted the curtain on new data for its C5 complement inhibitor ALXN1210, demonstrating its non-inferiority to another of …
FDA moots a return look at Acadia’s lead drug
April 27, 2018Medical Communications, Sales and Marketing Acacia, FDA, nuplazid, pharma
Following a non-profit report that higher rates of death were associated with Acadia Pharmaceuticals’ Nuplazid, Scott Gottlieb has made comments …
Health to hand
April 26, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Breast Cancer Care, biotech, drugs, pharma, pharmaceutical
Kristina Barrick is the Digital Innovation Manager at Breast Cancer Care and leads on the development of BECCA, the Breast …
US court upholds verdict voiding MSD’s claim to $200m from Gilead in patent dispute
April 26, 2018Sales and Marketing Gilead, MSD, Merck, harvoni, hepatitis C, pharma, sovaldi
MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
